Member Info for Ollieh

Yep...big hitters from two of the biggest pharma companies out there....they must see a serious MC here in the next few years.

All going to plan then....mighty stuff.

You died 3 years ago. Fri, 13th Jun 2014 07:00 RNS Number : 5399J Tower Resources PLC 13 June 2014 Hard luck all....cheers.

Yes ...I like the feel of summ more and more now.

Liking us last few days.

?

Yes maybe.

Yes more big buys today ;-)

Yep...about 11 chunky buys today......got a great feeling about this one .

Thanks free.....I think we have a cracking share here with huge potential......proper big money future...excellent.

At the end today....tasty.

I have a feeling this is gonna be big. ......got that buzz back here.

Like I said before. ..I think this will be my new ELAN like pharma.....I remember those days with fondness. ..going from €1.10 up to over €22.... good times ahead all going well.....good buzz starting again.

With all going well we should have a very very good pharma company with massive earning potential. ..but hopefully on the back of helping a lot of sick people get better and have those lads have a better and longer life...gla.

"$22 million milestone upon the first dosing of the last patient in Summit's PhaseOut DMD trial"

"Under the terms of the agreement, Summit will receive an upfront fee of $40 million. In addition, Summit will be eligible for future ezutromid related development, regulatory and sales milestone payments totalling up to $522 million, including a $22 million milestone upon the first dosing of the last patient in Summit's PhaseOut DMD trial, and escalating royalties ranging from a low to high teens percentage of net sales in the licensed territory. Summit will also be eligible to receive development and regulatory milestones related to its next-generation utrophin modulators. Sarepta and Summit will share specified utrophin modulator-related research and development costs at a 45%/55% split, respectively, beginning in 2018. If Sarepta elects to exercise its option for Latin American rights, Summit would be entitled to additional fees, milestones and royalties." All in RNS.

Lazy journalist who printed that news. Tut tut .

lse would sort out this site....SP reporting is crazyb at times.

Or '''me thinks ''

'' FDA also confirmed that ridinilazole would be eligible for Priority Review based on its QIDP designation '' And trump may pave the way for helping fast track new drugs.........good time to be in pharma me ghinks.